BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, May 2, 2024
See today's BioWorld
Home
» VIA Pops on Subset Analysis from Phase II ACS Trial with VIA-2291
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
VIA Pops on Subset Analysis from Phase II ACS Trial with VIA-2291
May 4, 2009
By
Trista Morrison
No Comments
Shares of VIA Pharmaceuticals Inc. jumped 45 percent Friday after the company presented a Phase II subset analysis showing that VIA-2291 reduced unstable coronary plaques in patients with acute coronary syndrome. (BioWorld Today)
BioWorld